Welcome to CSNpharm! For Research Use Only!
Cholecystokinin Receptor
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN26386 | YM022 | 145084-28-2 | YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively[1]. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo[3]. |
| CSN22513 | SR 146131 | 221671-61-0 | SR 146131 is a potent, orally active and selective nonpeptide cholecystokinin subtype 1 receptor agonist on IMR-32 human neuroblastoma cells. |
| CSN13775 | Rebamipide | 90098-04-7 | Rebamipide is an inducer of endogenous prostaglandin, an oxygen-derived free radical scavenger, and a cholecystokinin type 1 (CCK1) receptor inhibitor for inhibiting 125IBH-CCK-8S with IC50 of 37.7 M. |
| CSN23839 | Proglumide | 6620-60-6 | Proglumide is a known cholecystokinin (CCK) antagonist. |
| CSN18099 | Nastorazepide | 209219-38-5 | Nastorazepide is a selective orally available 15-benzodiazepine-derivative gastrincholecystokinin 2 CCK-2 receptor antagonist with potential antineoplastic activity |
| CSN21716 | Loxiglumide | 107097-80-3 | Loxiglumide is a cholecystokinin (CCK) receptor antagonist. |
| CSN26412 | Devazepide | 103420-77-5 | Devazepide is a potent, competitive, selective and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor, with IC50s of 81 pM, 45 pM and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively. Devazepide is effective for gastrointestinal disorders[1]. |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
